Overview

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2018-08-21
Target enrollment:
Participant gender:
Summary
The aim of the study is to investigate the longterm impact on cardiovascular morbidity and mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g., weight and hypoglycaemia) of treatment with linagliptin in patients with type 2 diabetes at elevated cardiovascular risk receiving usual care, and compare outcome against glimepiride.
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Collaborator:
Eli Lilly and Company
Treatments:
Glimepiride
Linagliptin